Anupama Pasam

1.1k total citations
18 papers, 591 citations indexed

About

Anupama Pasam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Anupama Pasam has authored 18 papers receiving a total of 591 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Anupama Pasam's work include Prostate Cancer Treatment and Research (7 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anupama Pasam is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Immunotherapy and Immune Responses (6 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Anupama Pasam collaborates with scholars based in Australia, Belgium and South Africa. Anupama Pasam's co-authors include Jonathan Cebon, Miles C. Andrews, Katherine Woods, Sarah M. Russell, Mandy Ludford‐Menting, Jane Oliaro, Nigel J. Waterhouse, Ashley Knights, Laura J. Vella and Faruk Sacirbegovic and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Anupama Pasam

16 papers receiving 586 citations

Peers

Anupama Pasam
Anupama Pasam
Citations per year, relative to Anupama Pasam Anupama Pasam (= 1×) peers Paola Baldassari

Countries citing papers authored by Anupama Pasam

Since Specialization
Citations

This map shows the geographic impact of Anupama Pasam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anupama Pasam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anupama Pasam more than expected).

Fields of papers citing papers by Anupama Pasam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anupama Pasam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anupama Pasam. The network helps show where Anupama Pasam may publish in the future.

Co-authorship network of co-authors of Anupama Pasam

This figure shows the co-authorship network connecting the top 25 collaborators of Anupama Pasam. A scholar is included among the top collaborators of Anupama Pasam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anupama Pasam. Anupama Pasam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Gupta, Santosh, David Bourdon, Anis Hamid, et al.. (2024). Detection of PSMA expression on circulating tumor cells by blood-based liquid biopsy in prostate cancer. PubMed. 13(1). 1–6. 3 indexed citations
2.
Yang, Tianpei, Maria Doyle, Angela Pizzolla, et al.. (2023). Spatial analysis with SPIAT and spaSim to characterize and simulate tissue microenvironments. Nature Communications. 14(1). 2697–2697. 38 indexed citations
4.
Trigos, Anna, Anupama Pasam, Vinita Gupta, et al.. (2023). Heterogeneity of canonical prostate cancer markers across lesions in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). 219–219.
5.
Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2022). PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(16_suppl). 5017–5017. 34 indexed citations
6.
Hamid, Anis, Michael S. Hofman, Mathias Bressel, et al.. (2022). Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 40(16_suppl). 5027–5027. 2 indexed citations
7.
Duarte, Jessica Da Gama, Katherine Woods, Candani Tutuka, et al.. (2021). Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. Cancers. 13(8). 1805–1805. 1 indexed citations
8.
Sandhu, Shahneen, Anthony M. Joshua, Louise Emmett, et al.. (2021). 577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S626–S627. 14 indexed citations
9.
Trigos, Anna, Anupama Pasam, Patricia Banks, et al.. (2020). The tumor immune microenvironment of germline BRCA1/2 and sporadic prostate cancer.. Journal of Clinical Oncology. 38(6_suppl). 152–152. 1 indexed citations
10.
Duarte, Jessica Da Gama, Sagun Parakh, Miles C. Andrews, et al.. (2018). Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. Frontiers in Immunology. 9. 411–411. 47 indexed citations
11.
Vella, Laura J., Anupama Pasam, Nektaria Dimopoulos, et al.. (2014). MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. Cancer Immunology Research. 2(4). 351–360. 116 indexed citations
12.
Vella, Laura J., Miles C. Andrews, Anupama Pasam, et al.. (2014). The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations. OncoImmunology. 3(7). e946367–e946367. 9 indexed citations
13.
Woods, Katherine, Anupama Pasam, Aparna Jayachandran, Miles C. Andrews, & Jonathan Cebon. (2014). Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells. Frontiers in Oncology. 4. 367–367. 27 indexed citations
14.
Vella, Laura J., Anupama Pasam, Nektaria Dimopoulos, et al.. (2013). MEK inhibition, alone or in combination with BRAF inhibition, impairs multiple functions of isolated normal human lymphocytes and dendritic cells. Journal for ImmunoTherapy of Cancer. 1(S1). 6 indexed citations
15.
Knights, Ashley, Jitka Fučíková, Anupama Pasam, Sandra Koernig, & Jonathan Cebon. (2012). Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. Cancer Immunology Immunotherapy. 62(2). 321–335. 27 indexed citations
16.
Ludford‐Menting, Mandy, Blessing Crimeen‐Irwin, Jane Oliaro, et al.. (2011). The Reorientation of T-Cell Polarity and Inhibition of Immunological Synapse Formation by CD46 Involves Its Recruitment to Lipid Rafts. SHILAP Revista de lepidopterología. 2011. 1–10. 15 indexed citations
17.
Oliaro, Jane, Anupama Pasam, Nigel J. Waterhouse, et al.. (2006). Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. Proceedings of the National Academy of Sciences. 103(49). 18685–18690. 38 indexed citations
18.
Ludford‐Menting, Mandy, Jane Oliaro, Faruk Sacirbegovic, et al.. (2005). A Network of PDZ-Containing Proteins Regulates T Cell Polarity and Morphology during Migration and Immunological Synapse Formation. Immunity. 22(6). 737–748. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026